Larissa A. Meyer - Concepedia

Author

Larissa A. Meyer

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Kwang Yeong How, L Meyer, L. A. Meyer, L. Meyer, L.A. Meyer, LOUISE MEYER, Larissa A. Meyer, Larissa A Meyer, Larissa A. Meyer, Larissa Alejandra Meyer

430

Publications

8.4K

Citations

H-Index

144

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Harvard University Dana-Farber Cancer Institute Gynecologic Oncology Group

About

Larissa A. Meyer is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, obstetrics, and gynecology oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	55	2.2K
2	Public Health	11	11	397
3	Health Sciences	4	4	134
4	Nursing	4	4	192
5	Social Sciences	1	1	13

Larissa A. Meyer

103

Publications

Citations

H-Index

Page 1

	Year	Citations
Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations—2019 update Gregg Nelson, Jamie N. Bakkum‐Gamez, Eleftheria Kalogera, International Journal of Gynecological Cancer	2019	705
Guidelines for postoperative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations — Part II Gregg Nelson, Alon D. Altman, Alpa M. Nick, Gynecologic Oncology	2016	547
Guidelines for pre- and intra-operative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations — Part I Gregg Nelson, Alon D. Altman, Alpa M. Nick, Gynecologic Oncology	2015	451
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline Alexi A. Wright, Kari Bohlke, Deborah K. Armstrong, Journal of Clinical Oncology	2016	401
Somatic Mutations in <i>BRCA1</i> and <i>BRCA2</i> Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer Bryan T. Hennessy, Kirsten M. Timms, Mark Carey, Journal of Clinical Oncology	2010	368
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline Alexi A. Wright, Kari Bohlke, Deborah K. Armstrong, Gynecologic Oncology Neoadjuvant ChemotherapyAdvanced Ovarian CancerMedicineCancer ManagementGynecology	2016	359
Promoter Hypermethylation of <b> <i>FANCF</i> </b> Gopeshwar Narayan, Hugo Arias‐Pulido, Subhadra V. Nandula, Cancer Research	2004	189
Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device Navdeep Pal, Russell R. Broaddus, Diana L. Urbauer, Obstetrics and Gynecology	2017	184
Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. Frank H. Valone, Peter A. Kaufman, Paul M. Guyre, Journal of Clinical Oncology	1995	183
Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer Alexi A. Wright, Angel M. Cronin, Dana Milne, Journal of Clinical Oncology	2015	177

Page 1